Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities—Quo Vadis?
National Institute on Drug Abuse · Johns Hopkins University · +5 more institutions
Abstract
Importance: Glucagon-like peptide-1 (GLP-1) therapies have revolutionized the management of chronic conditions like obesity and diabetes. Consistent with the overlap between feeding and metabolic pathways and those mediating addictive behaviors, growing evidence suggests that GLP-1 therapies may also be beneficial for treating alcohol and other substance use disorders (ASUDs). This review discusses the current landscape of GLP-1 therapies in the context of ASUDs, mental health considerations, and gaps and opportunities in this field. Observations: Preclinical evidence across several experimental models and species consistently shows that GLP-1 receptor agonists (GLP-1RAs) reduce drug intake and other addictive…
Citation impact
- FWCI
- 112.15
- Percentile
- 100%
- References
- 87
Authors
2- MFMehdi FarokhniaCorresponding
National Institute on Drug Abuse, Johns Hopkins University, National Institute on Alcohol Abuse and Alcoholism
- LLL. Leggio
National Institute on Drug Abuse, Johns Hopkins University, Georgetown University, Brown University, Johns Hopkins Medicine, Georgetown University Medical Center, National Institute on Alcohol Abuse and Alcoholism
Topics & keywords
- Addiction
- Mental health
- Context (archaeology)
- Observational study
- MEDLINE
- Clinical trial
- Good health and well-being